Hims & Hers Health (NYSE:HIMS) Trading 9.1% Higher – Here’s What Happened

15 Apr 2026, 10:34 by Kim Johansen · The Markets Daily

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report)’s stock price rose 9.1% during mid-day trading on Monday . The company traded as high as $20.98 and last traded at $21.2050. Approximately 10,095,123 shares changed hands during trading, a decline of 69% from the average daily volume of 32,452,229 shares. The stock had previously closed at $19.43.

Analysts Set New Price Targets

HIMS has been the topic of several research analyst reports. TD Cowen lowered their price target on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a report on Friday, March 27th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. BTIG Research downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating in a research note on Tuesday, February 24th. Needham & Company LLC upgraded Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a research note on Monday, March 9th. Finally, Truist Financial restated a “hold” rating and issued a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $31.71.

Get Our Latest Report on Hims & Hers Health

Hims & Hers Health Stock Up 1.1%

The business has a 50 day simple moving average of $19.53 and a 200 day simple moving average of $32.76. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The stock has a market cap of $4.88 billion, a PE ratio of 41.94, a P/E/G ratio of 2.01 and a beta of 2.32.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. During the same quarter in the previous year, the company posted $0.11 earnings per share. The business’s quarterly revenue was up 28.4% compared to the same quarter last year. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Irene Becklund sold 5,529 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $136,511.01. Following the completion of the sale, the insider owned 8,752 shares in the company, valued at approximately $216,086.88. This represents a 38.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Soleil Boughton sold 4,812 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $118,808.28. Following the sale, the insider owned 308,831 shares of the company’s stock, valued at approximately $7,625,037.39. This trade represents a 1.53% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 129,889 shares of company stock worth $3,230,986. Insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several large investors have recently made changes to their positions in HIMS. Farallon Capital Management LLC boosted its stake in shares of Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after acquiring an additional 2,533,271 shares in the last quarter. Norges Bank bought a new stake in shares of Hims & Hers Health during the 4th quarter worth about $62,153,000. Invesco Ltd. boosted its stake in shares of Hims & Hers Health by 62.7% during the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after acquiring an additional 1,600,004 shares in the last quarter. Clear Street Group Inc. bought a new stake in shares of Hims & Hers Health during the 3rd quarter worth about $87,372,000. Finally, Marex Group plc boosted its stake in shares of Hims & Hers Health by 162.2% during the 4th quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock worth $78,562,000 after acquiring an additional 1,496,707 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.